Q-omics provides the consensus-scored ZNF573 profile across patient tissues and cancer cell-line models. ZNF573 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, ZNF573 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, ZNF573 RNA expression shows 21,125 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UCS, THCA, and KIRP as cancer lineages where ZNF573 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF573 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF573 survival associations across molecular data types. ZNF573 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF573 RNA expression–survival associations across cancer types. High ZNF573 expression shows unfavorable associations in CESC, LGG, LUSC and LIHC, but favorable associations in UCS and KIRC. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .007). Together, the overview and detailed table identify UCS as the clearest survival context for ZNF573 RNA expression.
This table summarizes ZNF573 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF573. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF573 shows lower tumor expression in THCA and KICH and higher tumor expression in LIHC, COAD, CHOL and LUAD. The THCA box plot shows higher ZNF573 RNA expression in normal versus tumor tissue (log2 FC = −0.714, t-test p < 0.001).
This table shows molecular features associated with ZNF573 in patient tissues and cancer cell lines. In patient samples, ZNF573 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF573 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
